Estradiol/nomegestrol monophasic

Drug Profile

Estradiol/nomegestrol monophasic

Alternative Names: E2-Nomac monophasic; E2/Nomac monophasic; EMM-310066; IOA; MK-8175A; NOMAC-E2; Nomac-E2 monophasic; NOMAC/E2; Nomac/E2 monophasic; Nomegestrol acetate/17 beta-estradiol; Nomegestrol acetate/estradiol; Nomegestrol/estradiol; Org 10486-0/Org 2317; SCH 900121; Zoely

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Theramex SAM
  • Developer Merck & Co
  • Class Estradiol congeners; Estrenes; Hormonal contraceptives; Hormonal replacements; Pregnadienes; Progesterone congeners; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pregnancy

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 03 Dec 2014 Merck terminates phase III trial in Contraception/Pregnancy (Prevention) in USA (NCT01656434)
  • 10 Feb 2014 Teva Pharmaceutical Industries has patent protection for estradiol/nomegestrol monophasic in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top